GlassScriptPhysician profile
Tonya M Millsaps
NPI 1770502585
$5,987.16
in general payments reported to CMS, 2019-2025
36 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 84% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $940 · 2022: $951 · 2023: $1,367 · 2024: $1,637 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,980 · Education: $116.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,980.33 |
| Education | $116.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $972.38 | 2021-2025 | Airsupra, Farxiga, Breztri |
| Novo Nordisk INC | $966.32 | 2021-2025 | Ozempic, Wegovy, Rybelsus |
| Abbvie INC. | $880.31 | 2021-2025 | |
| Pfizer INC. | $413.44 | 2021-2025 | |
| Amgen INC. | $344.78 | 2021-2024 | Evenity, Prolia, Otezla |
| Lilly USA, LLC | $281.66 | 2021-2024 | Mounjaro, Jardiance, Zepbound |
| Glaxosmithkline, LLC. | $270.19 | 2021-2025 | Trelegy Ellipta, Shingrix |
| Boehringer Ingelheim Pharmaceuticals, INC. | $156.94 | 2022-2025 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $142.32 | 2022-2025 | |
| Dexcom, INC. | $129.42 | 2022-2024 | Dexcom G6 Transmitter |
| Biohaven Pharmaceuticals, INC. | $125.00 | 2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $121.91 | 2021-2025 | Trintellix |
| Sanofi-Aventis U.S. LLC | $107.89 | 2021-2023 | |
| Exact Sciences Corporation | $104.71 | 2023-2025 | Cologuard Collection Kit |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $103.76 | 2022-2025 | Xifaxan |
Show all 36 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $98.66 | 2023-2025 | Caplyta |
| Motiva USA, LLC | $86.89 | 2025 | |
| Astellas Pharma US INC | $72.08 | 2021-2024 | Veozah |
| Lundbeck LLC | $68.93 | 2023-2025 | Rexulti, Vyepti |
| Axsome Therapeutics, INC. | $67.93 | 2024 | Auvelity |
| Merck Sharp & Dohme LLC | $60.88 | 2021-2022 | |
| Otsuka America Pharmaceutical, INC. | $54.16 | 2023-2024 | Rexulti |
| Almatica Pharma LLC | $49.37 | 2022 | |
| Organon LLC | $45.88 | 2022-2024 | Nexplanon |
| Viatris Specialty LLC | $42.56 | 2025 | Yupelri |
| Phathom Pharmaceuticals, INC. | $34.55 | 2024-2025 | Voquezna |
| Sanofi Pasteur INC. | $34.40 | 2023-2024 | |
| Ironshore Pharmaceuticals INC. | $24.64 | 2024 | |
| Abbott Laboratories | $24.19 | 2022 | |
| Novartis Pharmaceuticals Corporation | $20.18 | 2023 | |
| Kowa Pharmaceuticals America, INC. | $16.27 | 2025 | Zoryve |
| Biohaven Pharmaceutical Holding Company LTD. | $15.49 | 2022 | |
| Neos Therapeutics, LP | $14.18 | 2024 | Adzenys Xr-Odt |
| Amarin Pharma, INC. | $13.09 | 2021 | |
| Mannkind Corporation | $13.00 | 2023 | Afrezza |
| Genentech USA, INC. | $8.80 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tonya Millsaps listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.